Clinical Trials

Find a Trial

Trial Results

79 protocol(s) meet the specified criteria
14-13546OPEN TO ACCRUAL
Pathogen Identification in Pediatric Hematopoietic Stem Cell Transplant Patients with Suspected Lower Respiratory Tract Infection
ADVL1514OPEN TO ACCRUAL
A PHASE 1 STUDY OF ABI-009 (NAB-RAPAMYCIN) IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS AS A SINGLE AGENT AND IN COMBINATION WITH TEMOZOLOMIDE AND IRINOTECAN
CABOZANTINIBOPEN TO ACCRUAL
NF-105: A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects with Neurofibromatosis Type 1 age 16-65 years
EAY131/MATCHOPEN TO ACCRUAL
Molecular Analysis for Therapy Choice (MATCH)
IUCRO-0049OPEN TO ACCRUAL
Immunologic, Genetic, Molecular, and Pathological Correlates with Clinical and Treatment Outcome in Patients with Renal Cell Carcinoma
IUCRO-0280OPEN TO ACCRUAL
IU Simon Cancer Center Tissue Bank
IUCRO-0429OPEN TO ACCRUAL
Resilience Profile for Adolescents and Young Adults with Cancer and Parents
IUSCC-0545OPEN TO ACCRUAL
Active Music Engagement to Manage Acute Distress and Improve Positive Health Outcomes in Young Children undergoing HSCT and Parents
IUSCC-0578OPEN TO ACCRUAL
Mechanisms of active music engagement to manage acute distress and improve positive health outcomes in young children with cancer and parents
IUSCC-0586OPEN TO ACCRUAL
Biomarkers of endothelial dysfunction in pediatric patients receiving high intensity chemotherapy/irradiation
IUSCC-0599OPEN TO ACCRUAL
Identifying Patient-Centered Outcomes for Children with Cancer and Their Caregivers When They Seek Care in the Emergency Department
IUSCC-0601OPEN TO ACCRUAL
Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children
PHO-ASTELLAS-9766-CL-0046OPEN TO ACCRUAL
A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous Isavuconazonium Sulfate in Pediatric Patients.
PHO-BMS-FALLON-AHOD1721OPEN TO ACCRUAL
Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after failure of first-line therapy, followed by brentuximab + bendamustine (Bv + B) for participants with a suboptimal response. CheckMate 744: CHECKpoint pathway and nivolumab clinical Trial Evaluation
PHO-CIBMTR-DELGADO-13TLECOPEN TO ACCRUAL
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
PHO-COG-CROOP-ADVL1212OPEN TO ACCRUAL
ADVL1212, A Phase 1 Study of Crizotinib (IND# 105573) in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
PHO-COG-CROOP-ADVL1217OPEN TO ACCRUAL
ADVL1217, A Phase 1 Study of MK-1775(IND# 116495) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children with Diffuse Intrinsic Pontine Gliomas
PHO-COG-CROOP-ADVL1312OPEN TO ACCRUAL
ADVL1312, A Phase 1/2 Study of MK-1775 (AZD1775, IND# 121422) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
PHO-COG-CROOP-ADVL1411OPEN TO ACCRUAL
A PHASE 1/ 2 STUDY OF BMN 673 (IND# 121510), AN ORAL POLY(ADP-RIBOSE) POLYMERASE INHIBITOR, PLUS TEMOZOLOMIDE IN CHILDREN WITH REFRACTORY OR RECURRENT MALIGNANCIES
PHO-COG-CROOP-ADVL1412OPEN TO ACCRUAL
A PHASE 1/2 STUDY OF NIVOLUMAB (IND# 124729) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RECURRENT OR REFRACTORY SOLID TUMORS AS A SINGLE AGENT AND IN COMBINATION WITH IPILIMUMAB
PHO-COG-CROOP-ADVL1414OPEN TO ACCRUAL
A Phase 1 Study of Selinexor (KPT-330, IND# 125052), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors
PHO-COG-FALLON-AALL05B1OPEN TO ACCRUAL
A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
PHO-COG-FALLON-AALL08B1OPEN TO ACCRUAL
Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
PHO-COG-FALLON-AALL0932OPEN TO ACCRUAL
Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
PHO-COG-FALLON-AALL1131OPEN TO ACCRUAL
AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
PHO-COG-FALLON-AALL1231OPEN TO ACCRUAL
AALL1231 A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
PHO-COG-FALLON-AALL1331OPEN TO ACCRUAL
Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
PHO-COG-FALLON-AAML1031OPEN TO ACCRUAL
AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD
PHO-COG-FALLON-AAML1331OPEN TO ACCRUAL
A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid
PHO-COG-FALLON-ACCL1033OPEN TO ACCRUAL
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
PHO-COG-FALLON-ACNS0332OPEN TO ACCRUAL
Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Subjects
PHO-COG-FALLON-ACNS0831OPEN TO ACCRUAL
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
PHO-COG-FALLON-ADVL1622OPEN TO ACCRUAL
ADVL1622, Phase 2 Trial of XL184 (Cabozantinib), an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
PHO-COG-FALLON-AEWS07B1OPEN TO ACCRUAL
A Children's Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens
PHO-COG-FALLON-AEWS1031OPEN TO ACCRUAL
A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
PHO-COG-FALLON-AEWS1221OPEN TO ACCRUAL
Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
PHO-COG-FALLON-AGCT1531OPEN TO ACCRUAL
AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
PHO-COG-FALLON-AHEP0731OPEN TO ACCRUAL
Treatment of Children with All Stages of Hepatoblastoma
PHO-COG-FALLON-AHOD1331OPEN TO ACCRUAL
A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
PHO-COG-FALLON-ALTE03N1OPEN TO ACCRUAL
Key Adverse Events Following Childhood Cancer
PHO-COG-FALLON-ALTE07C1OPEN TO ACCRUAL
ALTE07C1, Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
PHO-COG-FALLON-ALTE11C1OPEN TO ACCRUAL
ALTE11C1, Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma
PHO-COG-FALLON-ANBL00B1OPEN TO ACCRUAL
Neuroblastoma Biology Studies
PHO-COG-FALLON-ANBL1221OPEN TO ACCRUAL
A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma
PHO-COG-FALLON-ANBL1232OPEN TO ACCRUAL
ANBL1232, Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
PHO-COG-FALLON-ANHL12P1OPEN TO ACCRUAL
A Randomized Phase II Trial of Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)
PHO-COG-FALLON-AOST1321OPEN TO ACCRUAL
Phase 2 Study of Denosumab (IND# 127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma
PHO-COG-FALLON-AOST1421OPEN TO ACCRUAL
A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038, IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma
PHO-COG-FALLON-AOST1521OPEN TO ACCRUAL
A Phase 2 Study of GPNMB-targeted Antibody-Drug Conjugate, CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE; IND# 128248, NSC# 763737), in Recurrent or Refractory Osteosarcoma
PHO-COG-FALLON-APEC14B1OPEN TO ACCRUAL
Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
PHO-COG-FALLON-AREN03B2OPEN TO ACCRUAL
Renal Tumors Classification, Biology, and Banking Study
PHO-COG-FALLON-ARST1321OPEN TO ACCRUAL
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)
PHO-COG-FALLON-D9902OPEN TO ACCRUAL
A Group Wide Protocol for Collecting and Banking Pediatric Cancer Research Specimens. An Intergroup Rhabdomyosarcoma Study Group Protocol
PHO-COG/EISAI-ADVL1711OPEN TO ACCRUAL
A Phase 1/2 Study of Lenvatinib in combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, including CNS tumors
PHO-CROOP-AMGEN-20110261OPEN TO ACCRUAL
A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects with Advanced Non Central Nervous System Tumors That are Amenable to Direct Injection Advanced Non Central Nervous SystemTumors That are Amenable to Direct Injection
PHO-CROOP-COG-ADVL1513OPEN TO ACCRUAL
A PHASE 1 STUDY OF ENTINOSTAT, AN ORAL HISTONE DEACETYLASE INHIBITOR, IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS AND LYMPHOMA
PHO-CROOP-COG-ADVL1515OPEN TO ACCRUAL
ADVL1515, A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors
PHO-CROOP-COG-ADVL1615OPEN TO ACCRUAL
A PHASE 1 STUDY OF PEVONEDISTAT (MLN4924, IND# 136078), A NEDD8 ACTIVATING ENZYME (NAE) INHIBITOR, IN COMBINATION WITH TEMOZOLOMIDE AND IRINOTECAN IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS
PHO-FALLON-COG-AALL15P1OPEN TO ACCRUAL
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement
PHO-FALLON-COG-AALL1621OPEN TO ACCRUAL
AALL1621, A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
PHO-FALLON-COG-ANHL1522OPEN TO ACCRUAL
A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
PHO-FALLON-COG-ARST1431OPEN TO ACCRUAL
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
PHO-FALON-INCYTE-AALL1521OPEN TO ACCRUAL
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway?Mutant Acute Lymphoblastic Leukemia
PHO-GSK-FALLON-ADVL1322OPEN TO ACCRUAL
A Phase II Study of Pazopanib (GW786034, NSC# 737754 in Children, Adolescents and Young Adults with Refractory Solid Tumors
PHO-IU-PRADHAN-PACEOPEN TO ACCRUAL
Psychological and Cognitive predictors of Exercise Behavior among Pediatric Cancers
PHO-LILLY-CROOP-ADVL1416OPEN TO ACCRUAL
A PHASE 1 STUDY OF RAMUCIRUMAB, A HUMAN MONOCLONAL ANTIBODY AGAINST THE VASCULAR ENDOTHELIAL GROWTH FACTOR-2 (VEGFR-2) RECEPTOR IN CHILDREN WITH REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS
PHO-LILLY-PRADHAN-JGDNOPEN TO ACCRUAL
I5B-MC-JGDN(a) A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors
PHO-MILL-DELG-1209009655OPEN TO ACCRUAL
A phase I study evaluating the addition of bortezomib to an established acute graft versus host disease (aGVHD) prophylaxis regimen in pediatric allogeneic hematopoietic stem cell transplant (alloHSCT) patients
PHO-PRADHAN-COG-AALL1631OPEN TO ACCRUAL
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
PHO-PRADHAN-COG-ACNS1422-OPEN TO ACCRUAL
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
PHO-PRADHAN-COG-ADVL1521OPEN TO ACCRUAL
A Phase 2 Study of the MEK Inhibitor Trametinib in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
PHO-PRADHAN-COG-ALTE16C1OPEN TO ACCRUAL
Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
PHO-PRADHAN-COG-APEC1621OPEN TO ACCRUAL
NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)MASTER VERSION CONTROL PROTOCOL
PHO-PRADHAN-MERK-ADVL1621OPEN TO ACCRUAL
A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)
PHO-SHIH-ABBVIE-VELIPARIBOPEN TO ACCRUAL
AbbVie Pre-Approval Access to Veliparib for a Patient with Atypical Meningioma
PHO-SHIH-ASTRA-SELUMETINIOPEN TO ACCRUAL
An intermediate access protocol for selumetinib for treatment of neurofibromatosis type 1 with inoperable, progressive/symptomatic plexiform neurofibromas
PHO-SHIH-NWC-HEADSTART4OPEN TO ACCRUAL
NEWLY DIAGNOSED CHILDREN (LESS THAN 10 YEARS OLD) WITH MEDULLOBLASTOMA AND OTHER CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS: CLINICAL AND MOLECULAR RISK-TAILORED INTENSIVE AND COMPRESSED INDUCTION CHEMOTHERAPY FOLLOWED BY CONSOLIDATION WITH EITHER SINGLE CYCLE (LOW RISK PATIENTS) OR RANDOMIZATION (HIGH RISK PATIENTS) TO either SINGLE-CYCLE or TO THREE TANDEM CYCLES OF MARROW-ABLATIVE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL RESCUE
PHO-VIK-NCI-KENYABURKITTSOPEN TO ACCRUAL
IMPROVEMENTS OF DIAGNOSIS, STAGING, AND SUPPORT OF CHILDREN WITH BURKITT LYMPHOMA
PHO-YMABS-201OPEN TO ACCRUAL
A Phase 3 Trial of Antibody hu3F8 and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary or Secondary Refractory Osteomedullary Disease